Current Sickle Cell Disease Management Guidelines
The most recent 2025 National Alliance of Sickle Cell Centers (NASCC) consensus recommendations establish that hydroxyurea/hydroxycarbamide (HU/HC) should be universally discussed starting at the 2-month visit for all children with sickle cell anemia, with disease-modifying therapy options reviewed at every annual comprehensive visit 1.
Core Disease-Modifying Therapy
Hydroxyurea/Hydroxycarbamide - First-Line Therapy
Initiate HU/HC discussion at 2 months of age for children with sickle cell anemia 1. The evidence supporting this is compelling:
- 50% reduction in pain episodes and hospitalizations in adults 1
- Up to 40% reduction in mortality with long-term use 1
- Significant decreases in acute chest syndrome, pain crises, hospitalizations, and unplanned transfusions in pediatric patients 1
For adults, strongly recommend hydroxyurea for those with 3 or more severe vaso-occlusive crises in any 12-month period, SCD pain or chronic anemia interfering with daily activities, or severe/recurrent acute chest syndrome 2. For infants, children, and adolescents, offer hydroxyurea treatment without requiring presence of symptoms (moderate strength recommendation) 2.
Additional FDA-Approved Disease-Modifying Agents
Six FDA-approved medications now exist for SCD management 3:
- L-glutamine: Reduces sickle cell crisis episodes by preventing cell damage
- Crizanlizumab-TMCA: Prevents hemoglobin sickling and reduces crisis episodes
- Voxelotor: Improves hemoglobin oxygen-binding capacity
- Casgevy and Lyfgenia: Gene therapy options
Review all disease-modifying therapy options at every annual comprehensive visit to ensure patients remain informed of available treatments 1.
Primary Stroke Prevention
Transcranial Doppler (TCD) Screening
Perform annual TCD examinations from ages 2 to 16 years in children with HbSS and HbSβ0 thalassemia 2. This is a strong recommendation with clear intervention thresholds:
- TCD velocity ≥200 cm/s requires long-term transfusion therapy to prevent stroke 2
- In low-middle-income settings, use TCD screening combined with hydroxyurea for primary stroke prevention 4
Neuroimaging and Cognitive Surveillance
Obtain brain MRI without sedation at least once in early-school-age children and once in adults with HbSS or HbSβ0 thalassemia to detect silent cerebral infarcts 4. This represents one of three recommendations with immediate clinical impact from the 2020 ASH cerebrovascular guidelines.
Conduct surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in all children 4, 5. The 2026 NASCC neurocognitive workgroup established specific standards for developmental and cognitive screening across the lifespan 5.
Infection Prevention
Administer daily oral prophylactic penicillin up to age 5 years 2. This strong recommendation addresses the increased infection risk inherent to SCD.
Acute Pain Management
Vaso-Occlusive Crisis
Initiate opioids rapidly for severe pain associated with vaso-occlusive crisis 2. The 2020 ASH pain guidelines emphasize that most pain management recommendations are conditional due to low-certainty evidence, requiring patient preferences to drive decisions 6.
Use incentive spirometry in all patients hospitalized for vaso-occlusive crisis 2. This strong recommendation helps prevent acute chest syndrome.
Acute Chest Syndrome Management
The 2025 guidelines for emergencies and critical illness address 7:
- Imaging techniques (lung ultrasound, CT, echocardiography)
- Systemic corticosteroid treatment
- Non-invasive ventilation protocols
- Prophylactic and therapeutic anticoagulation
- Procalcitonin-guided antibiotic therapy
Transfusion Therapy
Transfuse preoperatively to increase hemoglobin to 10 g/dL (strong recommendation) 2.
Maintain sickle hemoglobin levels <30% prior to next transfusion during long-term transfusion therapy (moderate strength) 2.
Assess iron overload regularly and initiate chelation therapy when indicated 2. This addresses the inevitable consequence of chronic transfusion therapy.
Chronic Complications Management
Avascular Necrosis
Use analgesics and physical therapy for treatment 2.
Renal Disease
Prescribe ACE inhibitor therapy for microalbuminuria in adults 2.
Retinopathy
Refer patients with proliferative sickle cell retinopathy to expert specialists for consideration of laser photocoagulation 2.
Pulmonary Hypertension
Obtain echocardiography to evaluate signs of pulmonary hypertension 2.
Comprehensive Care Model
Establish care at a comprehensive, multidisciplinary SCD center aligned with NASCC standards 8. Real-world evidence from 2026 demonstrates that comprehensive centers achieve:
- Nearly 90% annual outpatient engagement by 2024
- Fifteen-fold increase in infusion therapy visits, providing alternatives to ED-based pain management
- Significant reduction in acute care visits from 2.11 to 1.26 per person per year
- Increased routine outpatient visits from 2.65 to 5.32 per person per year 8
This structural approach addresses the historical fragmentation of SCD care and reduces reliance on emergency services.
Critical Implementation Points
The 2025 NASCC consensus emphasizes that disease-modifying therapy discussions must occur at the 2-month visit and be revisited annually 1. This ensures patients have continuous access to evolving treatment options, including clinical trial participation when available.
Pain management requires interdisciplinary care with both pharmacological and non-pharmacological interventions 6. The evidence base remains limited, making most recommendations conditional and requiring shared decision-making.
Address social determinants of health as they significantly impact racially and ethnically minoritized communities living with SCD, creating substantial barriers to care access 1.